You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:

Continue

Go back

MLT_GIB/OTH/0007/17m
Date of preparation: March 2018

Introducing Synflorix

Synflorix is indicated for active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 5 years of age. 1

Refer to the product information for information on specific pneumococcal serotypes.

Why Synflorix

 

Resources

Patient Support

Access patient material and downloadable tools to help you in your practice.

Read More

Reference:

  1. Synflorix Global Data Sheet. 2016
  2. Monasta L, et al. Burden of Disease Caused by Otitis Media: Systematic Review and Global Estimates. PLoS One 2012; 7: e36226
  3. National Heart Lung and Blood Institute. Who is at risk for Pneumonia? Available at: https://www.nhlbi.nih.gov/health-topics/pneumonia [Last accessed February 2017].
  4. Public Health England. Pneumococcal disease. Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/ [Last accessed February 2017].
  5. UNICEF/WHO, Pneumonia: the forgotten killer of children, 2006

 

Synflorix is a trade mark of the GlaxoSmithKline group of companies.